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To The Editor
We thank Siegfried et al. (Siegfried et al., 2017) for their thoughtful response to our recent editorial (Flohr and Weidinger, 2016) (oral corticosteroids) when it comes to treating children with severe AD and most commonly use cyclosporine (45.2%), methotrexate (29.6%), and mycophenolate mofetil (13.0%) as first line systemic agents, rather than oral corticosteroids (Totri et al., 2017) , which is in line with recommendations of guidelines for the treatment of pediatric and adult atopic dermatitis published by several different medical societies internationally (Weidinger and Novak, 2016) . In this context we welcome the authors' statement that 'during phase 4, a study using an off-label, standard-of-care treatment, like methotrexate, would be feasible and tremendously valuable for clinicians.' This would not only be valuable for dermatologists but also patients alike, as they would not be denied active therapy.
Drug efficacy is not everything, however, and there clearly are differences between European and US regulatory authorities and health service provision that additionally come into play. For instance, cyclosporine, not oral corticosteroids, is the only licensed drug for the treatment of recalcitrant AD. Like Siegfried et al. we feel that systematic reviews of placebo-controlled trials are compromised by methodological diversity and differences in the study populations, making direct comparisons between therapies difficult. In our view, this is another good argument for active-comparator trials.
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It is important to keep in mind, however, that RCTs cannot answer all important questions. Due to very stringent inclusion and exclusion criteria the patients they recruit are often not representative of the patients we encounter in daily clinical practice. They are relatively short and rarely follow patients up post treatment cessation and thus do not provide data on long-term disease control and drug safety. This requires observational cohorts of 'real world' AD patients. With this in mind, the international TREAT (TREatment of ATopic dermatitis) Registry Taskforce has been set up to M A N U S C R I P T
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4 harmonize data collection in national AD treatment registries across country and continental borders, and we look forward to working with our North American colleagues on this important project (http://www.comet-initiative.org/studies/details/825).
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